Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amee Rozanc

Physician Assistant O Fallon, MO Physician Assistant

NPI 1255516134 CMS profile 10954912

9209 Phoenix Village Pkwy, O Fallon, MO 63366

Open in the dashboard

General payments

$101,414

922 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amee Rozanc of O Fallon, MO is reported in the CMS Open Payments database as having received $101,414 across 922 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53,144 224
2024 General $31,732 267
2023 General $13,395 205
2022 General $1,408 98
2021 General $1,736 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amee Rozanc
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Amee Rozanc were reported at $53,144. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Amee Rozanc Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,736 $132 $37–$438 $132
2022 $1,408 $155 $48–$522 $149
2023 $13,395 $167 $52–$557 $160
2024 $31,732 $178 $55–$600 $164
2025 $53,144 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $52,093 168 payments
  2. E.R. Squibb & Sons, L.L.C. $39,856 137 payments
  3. Amgen Inc. $1,508 121 payments
  4. Dermavant Sciences, Inc. $1,418 94 payments
  5. AbbVie, Inc. $1,089 118 payments
  6. LEO Pharma Inc. $839 63 payments
  7. Novartis Pharmaceuticals Corporation $742 25 payments
  8. Galderma Laboratories, L.P. $741 36 payments
  9. UCB, Inc. $566 21 payments
  10. Sun Pharmaceutical Industries Inc. $462 28 payments
  11. Other $2,101 111 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,829 46 payments
  2. Food and Beverage $16,487 822 payments
  3. Travel and Lodging $15,081 43 payments
  4. Consulting Fee $4,594 5 payments
  5. Education $423 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $52,032 160 payments
  2. SOTYKTU $34,957 121 payments
  3. VTAMA $1,613 106 payments
  4. Otezla $1,508 121 payments
  5. ADBRY $661 26 payments
  6. Bimzelx $514 19 payments
  7. RINVOQ $471 66 payments
  8. AKLIEF $436 17 payments
  9. SKYRIZI $419 34 payments
  10. DUPIXENT $357 15 payments
  11. Other $4,642 282 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

508

Median for Physician Assistant: 241

Drug cost

$125,884

Median for Physician Assistant: $4,110

Branded share of claims

6.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 20 $113,597
Clobetasol Propionate Generic 73 $2,669
Ketoconazole Generic 129 $2,662
Calcipotriene Generic 13 $1,303
Fluorouracil Generic 13 $1,181
Triamcinolone Acetonide Generic 102 $980
Metronidazole Generic 18 $893
Clindamycin Phosphate Generic 14 $795
Doxycycline Hyclate Generic 48 $697
Valacyclovir Valacyclovir Hcl Brand 14 $361

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$55,952

Of which drugs: $825

Medicare patients

325

Average age 73

Services billed

2,087

202 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Diabetes 22%
Ischemic heart disease 19%
Chronic kidney disease 18%
Depression 17%
Atrial fibrillation 15%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$21,244 — —
TREMFYA
$5,129 — —
VTAMA
$556 — —
ADBRY
$268 — —
Otezla
$179 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

922 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record